Listed
2016-11
First close
USD 30.45
split-adjusted
Since listing
+235%
23 points
Current
USD 102.14
— · 2026-11-08 04:51 ET
Peak
USD 102.14
—2026-11
Low
USD 84.24
—2026-10
Latest change
+1.3%
2026-11-05 → 2026-11-06
Change since first
+19.1%
2026-10
52-week range
USD 74.66 – USD 104.17
Drawdown
-1.9%
Avg vol 3m
3.7M
Price history
2026–2026Monthly closes from Yahoo Finance, split-adjusted, dividends excluded. Earlier points are actual closes, not reconstructed.
DateCloseChange
- 11-06USD 102.14+1.3%
- 11-05USD 100.82+1.5%
- 11-04USD 99.37+4.4%
- 11-03USD 95.19+2.1%
- 11-02USD 93.26+1.4%
- 10-30USD 92.01-2.6%
- 10-29USD 94.44+2.9%
- 10-28USD 91.78+1.1%
- 10-27USD 90.82+0.3%
- 10-26USD 90.56+1.7%
- 10-23USD 89.07-1.1%
- 10-22USD 90.09+1.9%
- 10-21USD 88.40+0.1%
- 10-20USD 88.29+1.2%
- 10-19USD 87.22+0.7%
- 10-16USD 86.60-1.7%
- 10-15USD 88.10+1.9%
- 10-14USD 86.45+1.4%
- 10-13USD 85.27-1.3%
- 10-12USD 86.39+1.4%
- 10-09USD 85.21+1.2%
- 10-08USD 84.24-1.8%
- 10-07USD 85.78—
Ownership & Control
Latest available filings- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →- Edwards Lifesciences Reports Q3 2026 Earnings: Revenue of $1.72 Billion Exceeds Estimates as TMTT Sales Surge 44%2026-11-04
- Edwards Lifesciences 2026 Q3 10-Q: Revenue Rises 10.5% to $1.72B with GAAP Diluted EPS of $0.532026-11-04
- MUFG Securities Publishes Updated Equity and Financial Disclosure Profile for Edwards Lifesciences Corporation2026-05-19